Canada markets close in 1 hour 33 minutes

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0203-0.0008 (-4.03%)
As of 02:06PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0211
Open0.0219
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0195 - 0.0219
52 Week Range0.0160 - 0.1060
Volume374,094
Avg. Volume437,419
Market Cap7.242M
Beta (5Y Monthly)-0.13
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

    NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it has completed the second and final tranche of its previously announced private placement (see January 24, 2024 and January 31, 2024 press releases) (the “Offering”) by issuing 33,917,428 units (each, a “U

  • GlobeNewswire

    Revive Therapeutics Explores the Use of Bucillamine for Long COVID

    TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company aims to advance the clinical development of Bucillamine by

  • GlobeNewswire

    Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500

    NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it has completed the first tranche of its previously announced private placement (see January 24, 2024 press release) (the “Offering”) by issuing 26,100,000 units (each, a “Unit”), at a price of $0.035 per U